ClinicalTrials.gg
CompletedNCT04494386ULSCUpdated Apr 9, 2024

Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

A Phase 1/2 interventional study of Umbilical Cord Lining Stem Cells (ULSC) and Placebo (carrier control) in Covid19, Corona Virus Infection and SARS-CoV Infection, sponsored by Restem, LLC.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-09.

Sponsored by Restem, LLC. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was May 2023, 3 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
1,071st of 1,322
17 · median 92
Started
2020
with 817 others
Phase 1/2
62 of 1,860
4 open now
Registered
566th of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 1,071st largest by enrollment of the 1,322 interventional ones that give a count, is one of 818 that started in 2020, is one of 62 in phase 1/2, and was the 566th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

ULSC-CV-01 is a clinical trial that comprises both Phase 1 and Phase 2a, which will be conducted sequentially. This trial will evaluate the safety and potential efficacy of allogeneic Umbilical Cord Lining Stem Cells (ULSC), which are a type of umbilical cord tissue derived mesenchymal stem cells (MSC), with intravenous (IV) administration in hospitalized patients with acute respiratory distress syndrome (ARDS) due to COVID-19.

Read the detailed description

The Phase 1, open-label, non-controlled trial in this study will investigate the safety of intravenous (IV) infusion of ULSC in a total of 20 patients with COVID-19-related ARDS that will include patients that are not intubated and not on a ventilator (NV) and patients that are intubated and on a ventilator (V) for respiratory support. Separate cohorts of each group (NV and V) will receive either a single dose (one infusion) or repeat dose (two infusions separated by 48-hour interval).

The Phase 2a randomized and placebo-controlled trial in this study will investigate the potential efficacy of IV infusion of ULSC in a total of 40 patients with COVID-19-related ARDS that will all be EITHER NV or V; the determination of that eligibility criterion and the ULSC dosing regimen will be based on Phase 1 data of safety and tolerability. Phase 2a will evaluate EITHER single dose (one infusion) or repeat dose (two infusions separated by 48-hour interval). The randomization will be 3:1 with 30 patients receiving investigational product (ULSC) and 10 patients receiving placebo (carrier control).

03

Conditions studied

  • Covid19
  • Corona Virus Infection
  • SARS-CoV Infection
  • ARDS
  • Coronavirus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult, male or female, age ≥18 years old
  2. Diagnosis of the presence of the COVID-19 agent with confirmation of COVID-19 by standard reverse transcriptase polymerase chain reaction (RT-PCR) or equivalent test.
  3. Patient with diagnosis of COVID-related ARDS, classified as either:

    • Not requiring mechanical ventilation (NV) or
    • Requiring mechanical ventilation (V).

    According to Berlin Definition of Acute Respiratory Distress Syndrome (ARDS), patients will be categorized based on degrees of hypoxemia [arterial partial pressure of oxygen (PaO2)/oxygen concentration (FiO2)]:

    • Mild ARDS: 200 mm Hg \< PaO2/FIO2 ≤ 300 mm Hg
    • Moderate ARDS: 100 mm Hg \< PaO2/FIO2 ≤ 200 mm Hg
    • Severe ARDS: PaO2/FIO2 ≤ 100 mm Hg
  4. Patient who has exhibited deterioration in condition during the past 72 hours prior to the .
  5. Patient receiving standard of care in-hospital therapy, including appropriate critical oxygenation, fluid, and hemodynamic support as indicated clinically.
  6. Patient or responsible family member or surrogate signs informed consent.

Exclusion criteria

Exclusion Criteria

  1. to study product components. History of hypersensitivity to dimethyl sulfoxide (DMSO).
  2. Active cancer or prior diagnosis of cancer within the past year; however, patients with basal and squamous cell cancer of skin will not be excluded.
  3. Organ transplant recipient.
  4. Chronic renal failure being treated by renal replacement therapy (dialysis) before development of COVID-19.
  5. Any other condition that, in the judgment of the Investigator or Sponsor, would be a to enrollment, study product administration, or follow-up.
  6. Pregnancy or lactation; a negative pregnancy test between screening and day 1 (before administration of treatment) will be required of women with , and they will be advised of the requirement to use an effective means of . A woman is considered to be of childbearing potential unless she is and without menses for 12 months or without a uterus and/or both ovaries.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    ULSC in Phase 1 Open Label

    Intravenous (IV) infusion of ULSC in 20 patients with COVID-19 ARDS: In Phase 1, two separate cohorts per group will receive either a single dose (one infusion) or repeat dose regimen (two infusions separated by 48-hour interval). The first cohort enrolled will receive the single dose; the next cohort enrolled will be administered the repeat dose regimen.

    Biological: Umbilical Cord Lining Stem Cells (ULSC)

  • Experimental
    ULSC in Phase 2a Randomized

    Intravenous (IV) infusion of ULSC in 30 patients with COVID-19 ARDS: In Phase 2a, 30 patients assigned ULSC will receive either a single dose (one infusion) or repeat dose regimen (two infusions separated by 48-hour interval). The ULSC dosing regimen will be chosen based on Phase 1 data of safety and tolerability.

    Biological: Umbilical Cord Lining Stem Cells (ULSC)

  • Placebo comparator
    Placebo in Phase 2a Randomized

    Intravenous (IV) infusion of carrier control in 10 patients with COVID-19 ARDS: In Phase 2a, 10 patients assigned Placebo will receive either single dose (one infusion) or repeat dose (two infusions separated by 48-hour interval) of carrier control; the dosing regimen will correspond to that of the experimental arm.

    Other: Placebo (carrier control)

Interventions

  • BiologicalUmbilical Cord Lining Stem Cells (ULSC)

    IV infusion of allogeneic ULSC (100 million cells per dose) in sterile saline for injection

    Also known as: Umbilical Cord Lining Stem Cells (ULSC), type of mesenchymal stem cells (MSC) derived from single donor umbilical cord tissue for allogeneic use

  • OtherPlacebo (carrier control)

    IV infusion of carrier control consisting of sterile saline for injection

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicity (DLT)

    Number of subjects with a DLT event during or within 24 hours after ULSC infusion \[Dose Limiting Toxicities are treatment-emergent suspected adverse reactions graded as severe, such as severe infusion-related hypersensitivity toxicities of grade ≥3, and any treatment-emergent serious adverse event (SAE) will be investigated to determine if DLT.\]

    Time frame: 24 hours

  2. Incidence of Dose Limiting Toxicity (DLT), suspected adverse reaction (SAR), or serious adverse event (SAE)

    Number of subjects with a DLT event, suspected adverse reaction, or any serious adverse event (SAE) within 1 week of each ULSC infusion

    Time frame: 1 week

  3. Treatment-emergent adverse events (AE) and serious adverse events (SAE)

    Treatment-emergent adverse events (AE; incidence, grade, and assessment of relatedness or causality) and serious adverse events (SAE) during the study up to 1-month follow-up

    Time frame: 1 month

  4. Treatment-emergent adverse events (AE) and serious adverse events (SAE)

    Treatment-emergent adverse events (AE; incidence, grade, and assessment of relatedness or causality) and serious adverse events (SAE) during the study and up to the 12-month follow-up

    Time frame: 12 months

Secondary outcomes

  1. Levels of COVID-19 related ARDS as defined by the Berlin Definition of ARDS

    Times to transitions between levels of COVID-19 related ARDS as defined by the Berlin Definition of ARDS

    Time frame: 1 month

  2. Changes from baseline pulse oximetric saturation SpO2/FiO2 ratio or arterial oxygen pressure pAO2/FiO2 ratio

    Changes in SpO2/FiO2 ratio or pAO2/FiO2 ratio compared to baseline, measured daily at a minimum; oxygenation index daily when on ventilator

    Time frame: 1 month

  3. Number of ventilator-free days (VFD)

    Number of ventilator-free days (VFD) in period of 1 month from study treatment

    Time frame: 1 month

  4. Changes in Complete Blood Count (CBC) with differential from baseline

    Changes in CBC with differential from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment

    Time frame: 1 month, 2 months, 3 months, 6 months, and 12 months

  5. Changes in levels of blood glucose (mg/dL) from baseline

    Changes in blood glucose (mg/dL) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment

    Time frame: 1 month, 2 months, 3 months, 6 months, and 12 months

  6. Changes in levels of sodium (mEq/L) from baseline

    Changes in levels of sodium (mEq/L) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment

    Time frame: 1 month, 2 months, 3 months, 6 months, and 12 months

  7. Changes in levels of potassium (mEq/L) from baseline

    Changes in levels of potassium (mEq/L) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment

    Time frame: 1 month, 2 months, 3 months, 6 months, and 12 months

  8. Changes in levels of blood urea nitrogen (BUN; mg/dL) from baseline

    Changes in levels of blood urea nitrogen (BUN; mg/dL) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment

    Time frame: 1 month, 2 months, 3 months, 6 months, and 12 months

  9. Changes in levels of alanine transaminase (ALT; U/L) from baseline

    Changes in levels of alanine transaminase (ALT; U/L) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment

    Time frame: 1 month, 2 months, 3 months, 6 months, and 12 months

  10. Change in Urinalysis (UA) from baseline

    Change in Urinalysis (UA) at baseline and 1 month after study treatment to assess for presence and qualitative proteinuria

    Time frame: 1 month

07

Study locations

2 sites
  • Miami Baptist Hospital
    Miami, Florida 33176, United States
  • Sanford Research
    Sioux Falls, South Dakota 57105, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in May 2023, 28 months.

Of 80 industry-sponsored phase 1/2 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 28 months is above that.

Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2020
First posted
Jul 31, 2020
StartActual
Dec 23, 2020
Primary completionActual
May 12, 2023
CompletionActual
May 12, 2023
Last update
Apr 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04494386
Lead sponsor
Restem, LLC.
Responsible party
Sponsor
First posted
Jul 31, 2020
Start date
Dec 23, 2020
Primary completion
May 12, 2023
Completion
May 12, 2023
Last update
Apr 9, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion